Impact - impact RWD domain protein Gene
Species: Rattus norvegicus
Gene Type: protein coding
Gene ID: 497198
Summary
Predicted to enable actin binding activity and ribosome binding activity. Predicted to be involved in several processes, including GCN2-mediated signaling; cellular response to starvation; and negative regulation of nitrogen compound metabolic process. Predicted to be located in cytoplasm. Predicted to be part of polysome. Orthologous to human IMPACT (impact RWD domain protein). [provided by Alliance of Genome Resources, Apr 2022]
Impact Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_001012235.1 | NP_001012235.1 | protein IMPACT |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
protein IMPACT |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(2)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-B2122 | Maltitol | 98.0% | Unkown | |
| HY-B2122R | Maltitol (Standard) | 96.15% | Unkown |
Clinical Phase
Bioactive Molecules
(3)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-153306 | Zovegalisib | Inhibitor | 98.80% | Phase 3 |
| HY-W013706 | Inosine-5'-triphosphate trisodium salt | 99.09% | Phase 3 | |
| HY-112749 | ME-344 | 99.80% | Phase 2 |
Inhibitory Antibodies
(1)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-P99359 | Elezanumab | Inhibitor | 99.91% | Phase 2 |
Pre-clinical Phase
Bioactive Molecules
(73)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-Y0882 | Hydroxylamine hydrochloride | Inhibitor | 99.9% | Unkown |
| HY-B0990 | Thiostrepton | Inhibitor | 99.80% | Unkown |
| HY-W034953 | Bathocuproine disulfonate disodium | 99.44% | Unkown | |
| HY-131697 | FeTPPS | Inhibitor | 99.9% | Unkown |
| HY-159062 | Goji Extract | Activator | / | Unkown |
| HY-W012848 | 1-Phenylethanamine | 99.14% | Unkown | |
| HY-N0123 | Aloin-A | 99.31% | Unkown | |
| HY-163707 | UR778Br | Inducer | 99.33% | Unkown |
| HY-N0507 | Rosavin | Inhibitor | 99.91% | Unkown |
| HY-N2500 | Deoxypodophyllotoxin | 99.86% | Unkown | |
| HY-B1839 | Fluazinam | 99.51% | Unkown | |
| HY-170620 | PARP1 PROTAC 180055 | Inhibitor | 98.90% | Unkown |
| HY-33914 | 4-Hydroxymethylpyrazole | 99.74% | Unkown | |
| HY-P3688A | β-Amyloid (1-38) TFA | 99.38% | Unkown | |
| HY-137910 | Tembotrione | Inhibitor | 99.41% | Unkown |
| HY-136528 | RA-9 | 98.57% | Unkown | |
| HY-148384 | UHMCP1 | 99.68% | Unkown | |
| HY-Y0882S1 | Hydroxylamine-d3 hydrochloride | 99% | Unkown | |
| HY-W035599 | Ir[p-F(t-Bu)-ppy]3 | 98% | Unkown | |
| HY-114395A | (R)-NVS-ZP7-4 | 98.80% | Unkown | |
| HY-124693 | DB1055 | Inducer | 99.68% | Unkown |
| HY-143226 | DK1 | Modulator | 99.69% | Unkown |
| HY-152095 | PPI-GIT1/β-Pix PPI-IN-1 | Inhibitor | 99.01% | Unkown |
| HY-B0439S1 | Sulfadoxine D3 | Inhibitor | 98.0% | Unkown |
| HY-N0123R | Aloin-A (Standard) | 98.52% | Unkown | |
| HY-P3688 | β-Amyloid (1-38) | / | Unkown | |
| HY-W250147 | Basic blue 26 | 92.33% | Unkown | |
| HY-181293 | PROTAC AAK1 degrader-1 | Degrader | / | Unkown |
| HY-W115741S | 1-Phenylethanamine-d3 | / | Unkown | |
| HY-109006 | Ilmetropium iodide | Inhibitor | / | Unkown |
| HY-109036A | (S)-Landipirdine | / | Unkown | |
| HY-111259 | Ro 31-1118 free base | / | Unkown | |
| HY-113958 | Difethialone | Inhibitor | 99.84% | Unkown |
| HY-113958S | Difethialone-d4 | / | Unkown | |
| HY-113958S1 | Difethialone-d4-1 | Inhibitor | / | Unkown |
| HY-117119 | VER-3323 | Agonist | / | Unkown |
| HY-117467 | BMT-108908 | / | Unkown | |
| HY-121299 | m-Chlorophenylbiguanide | ≥90.0% | Unkown | |
| HY-121700 | L-751788 | Inhibitor | / | Unkown |
| HY-125958 | AA9 | Inhibitor | / | Unkown |
| HY-139898 | S7958 | Antagonist | / | Unkown |
| HY-148384A | UHMCP1 dihydrochloride | Inhibitor | / | Unkown |
| HY-14998 | Halofenate | / | Unkown | |
| HY-155237 | LIN28-IN-1 | Inhibitor | / | Unkown |
| HY-156283 | Antibacterial agent 159 | / | Unkown | |
| HY-158220C | Hyaluronic acid methacryloyl (MW 50000) | / | Unkown | |
| HY-160685 | GW809897X | Inhibitor | / | Unkown |
| HY-160708 | Tie2 kinase inhibitor 3 | Inhibitor | / | Unkown |
| HY-161577 | BFC1103 | / | Unkown | |
| HY-163736 | mPGES-1/5-LOX-IN-1 | Inhibitor | / | Unkown |
| HY-163854 | HSP70-IN-6 | / | Unkown | |
| HY-178174 | MGB4 | Inhibitor | / | Unkown |
| HY-178176 | PROTAC CB1R Degrader-1 | / | Unkown | |
| HY-178497 | ZJK-807 | / | Unkown | |
| HY-178937 | Anticancer agent 284 | Inhibitor | / | Unkown |
| HY-179265 | D-CAM-14 | Inhibitor | / | Unkown |
| HY-184419 | YZZ-24 | / | Unkown | |
| HY-185122 | MS6178 | Activator | / | Unkown |
| HY-B0357B | Diclazuril sodium | Inhibitor | / | Unkown |
| HY-RS06797 | IMPACT Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W250169 | Secondary alcohol polyoxyethylene ether | / | Unkown | |
| HY-W587768 | Metoxadiazone | 99.08% | Unkown | |
| HY-Y0882S | Hydroxylamine-15N hydrochloride | / | Unkown | |
| HY-127098 | Kahweol linoleate | / | Unkown | |
| HY-164469 | CHMFL-48 | Inhibitor | / | Unkown |
| HY-170974 | SDH-IN-20 | Inhibitor | / | Unkown |
| HY-184610 | Selenium nanoparticles | / | Unkown | |
| HY-B0824A | (1R)-cis-Bifenthrin | / | Unkown | |
| HY-RS21873 | Impact Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS28390 | Impact Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W114420 | 3-Methyl-L-tyrosine | / | Unkown | |
| HY-W158160 | AGS1286 sodium | Inhibitor | / | Unkown |
| HY-W727209 | Fluazaindolizine | Inhibitor | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service